While the use of monoclonal anti-IL-17A antibodies was disappointing in rheumatoid arthritis and multiple sclerosis (5, 6), these therapeutics are now used with great success in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis (7, 8). Here, IL17A is linked to psoriatic arthritis.